Sector Gamma AS
OSLO, Q8
$461m in 40 US stocks at the end of 30 June 2026. The top 10 are 48.4% of the money. It changed about 22.2% of the portfolio this quarter.
Value
$461m
Stocks
40
Top 10 share
48.4%
Turnover
22.2%
What changed this quarter
New
Bought for the first time this quarter.
- Thermo Fisher ScientificTMO3.7% of the fund
- Regeneron PharmaceuticalsREGN2.1% of the fund
- Ascendis Pharma A/SASND1.2% of the fund
- Boston ScientificBSX1.1% of the fund
- Travere TherapeuticsTVTX1.0% of the fund
- CytokineticsCYTK0.8% of the fund
- Intellia TherapeuticsNTLA0.7% of the fund
Added
Bought more of a stock they already held.
- MedtronicMDT6.0% of the fund+26%
- Biomarin PharmaceuticalBMRN3.7% of the fund+23%
- CVS HealthCVS3.5% of the fund+15%
- Iqvia HoldingsIQV3.3% of the fund+94%
- Ionis PharmaceuticalsIONS3.3% of the fund+12%
- Becton DickinsonBDX3.1% of the fund+13%
- Abbott LaboratoriesABT2.9% of the fund+68%
- GE HealthCare TechnologiesGEHC2.9% of the fund+64%
- QiagenQGEN2.4% of the fund+77%
- Bio-Rad LaboratoriesBIO2.1% of the fund+40%
- AvantorAVTR1.9% of the fund+30%
- PTC TherapeuticsPTCT1.8% of the fund+33%
- Labcorp HoldingsLH1.6% of the fund+37%
- DexcomDXCM1.5% of the fund+82%
- Kura OncologyKURA1.0% of the fund+5%
- Crinetics PharmaceuticalsCRNX0.9% of the fund+22%
- Iovance BiotherapeuticsIOVA0.9% of the fund+8%
- ArdelyxARDX0.8% of the fund+33%
Cut
Sold some of their stake.
- Bristol-Myers SquibbBMY9.1% of the fund-12%
- MerckMRK6.0% of the fund-17%
- PfizerPFE5.2% of the fund-8%
- IncyteINCY4.2% of the fund-15%
- Zimmer Biomet HoldingsZBH2.7% of the fund-9%
- BiogenBIIB2.5% of the fund-40%
- Cardinal HealthCAH2.1% of the fund-26%
- AmgenAMGN2.1% of the fund-44%
- BrukerBRKR2.0% of the fund-40%
- Syndax PharmaceuticalsSNDX1.1% of the fund-15%
- OrganonOGN0.8% of the fund-28%
Sold out
Sold their entire stake.
Holdings
- Crinetics PharmaceuticalsCRNX
- Share
- 0.9%
- Value
- $4m
- Shares
- 114,628
+22%
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Bristol-Myers SquibbBMY | 9.1% | $42m | 726,115 | -12% |
| MerckMRK | 6.0% | $28m | 217,008 | -17% |
| MedtronicMDT | 6.0% | $28m | 352,437 | +26% |
| PfizerPFE | 5.2% | $24m | 1,004,215 | -8% |
| IncyteINCY | 4.2% | $19m | 170,753 | -15% |
| Elevance HealthELV | 3.7% | $17m | 44,499 | Held |
| Biomarin PharmaceuticalBMRN | 3.7% | $17m | 294,918 | +23% |
| Thermo Fisher ScientificTMO | 3.7% | $17m | 33,584 | New |
| CVS HealthCVS | 3.5% | $16m | 155,337 | +15% |
| Iqvia HoldingsIQV | 3.3% | $15m | 77,944 | +94% |
| Ionis PharmaceuticalsIONS | 3.3% | $15m | 189,468 | +12% |
| Becton DickinsonBDX | 3.1% | $14m | 93,168 | +13% |
| Abbott LaboratoriesABT | 2.9% | $13m | 147,444 | +68% |
| GE HealthCare TechnologiesGEHC | 2.9% | $13m | 207,863 | +64% |
| Zimmer Biomet HoldingsZBH | 2.7% | $12m | 142,307 | -9% |
| BiogenBIIB | 2.5% | $12m | 54,163 | -40% |
| QiagenQGEN | 2.4% | $11m | 287,640 | +77% |
| CenteneCNC | 2.3% | $10m | 162,405 | Held |
| Regeneron PharmaceuticalsREGN | 2.1% | $10m | 15,780 | New |
| Bio-Rad LaboratoriesBIO | 2.1% | $10m | 33,350 | +40% |
| Cardinal HealthCAH | 2.1% | $10m | 40,689 | -26% |
| AmgenAMGN | 2.1% | $10m | 26,281 | -44% |
| BrukerBRKR | 2.0% | $9m | 152,352 | -40% |
| AvantorAVTR | 1.9% | $9m | 906,088 | +30% |
| PTC TherapeuticsPTCT | 1.8% | $8m | 100,000 | +33% |
| Labcorp HoldingsLH | 1.6% | $7m | 26,019 | +37% |
| DexcomDXCM | 1.5% | $7m | 102,122 | +82% |
| Ascendis Pharma A/SASND | 1.2% | $6m | 21,305 | New |
| Edwards LifesciencesEW | 1.2% | $5m | 60,402 | Held |
| Syndax PharmaceuticalsSNDX | 1.1% | $5m | 241,739 | -15% |
| Boston ScientificBSX | 1.1% | $5m | 121,128 | New |
| Kura OncologyKURA | 1.0% | $5m | 433,012 | +5% |
| Travere TherapeuticsTVTX | 1.0% | $5m | 80,000 | New |
| Crinetics PharmaceuticalsCRNX | 0.9% | $4m | 114,628 | +22% |
| Tandem Diabetes CareTNDM | 0.9% | $4m | 267,091 | Held |
| Iovance BiotherapeuticsIOVA | 0.9% | $4m | 968,466 | +8% |
| CytokineticsCYTK | 0.8% | $4m | 45,000 | New |
| OrganonOGN | 0.8% | $4m | 270,781 | -28% |
| ArdelyxARDX | 0.8% | $4m | 686,844 | +33% |
| Intellia TherapeuticsNTLA | 0.7% | $3m | 185,177 | New |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 50.7% since 30 June 2025.
Where the money is
Health care100.0%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.